Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRB..L Share News (RB.)

  • There is currently no data for RB.

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 1-UK doctors to trial ibuprofen in COVID-19 patients with breathing difficulties

Wed, 03rd Jun 2020 16:37

(Adds interview with researcher)

LONDON, June 3 (Reuters) - British doctors are trialling a
formulation of anti-inflammatory ibuprofen to see if it reduces
respiratory failure in patients with severe symptoms of
COVID-19.

The trial involves a particular formulation of ibuprofen,
which researchers said had been shown to be more effective than
standard ibuprofen for treating severe acute respiratory
distress syndrome (ARDS), a complication of COVID-19.

The formulation is already licensed for use in Britain for
other conditions.

"If successful, the global public health value of this trial
result would be immense given the low cost and availability of
this medicine," said Matthew Hotopf, director of NIHR Maudsley
Biomedical Research Centre.

The trial, known as "LIBERATE", will be a randomised study,
with recruitment of up to 230 patients expected over the coming
months.

It is being run by Guy's & St Thomas' NHS Foundation Trust
in London, King's College London (KCL) and pharmaceutical
organisation the SEEK Group.

In March, France's health minister said people should not
use anti-inflammatory drugs such as ibuprofen if they have
symptoms of COVID-19, the disease caused by the new coronavirus.

However, U.S., British and European Union drug regulators as
well as Reckitt Benckiser, which makes Nurofen, have all
said there is no evidence that ibuprofen makes COVID-19 worse.

Mitul Mehta, director of KCL's Centre for Innovative
Therapeutics, said that possible well-known gastric side effects
from ibuprofen meant that paracetamol was better to relieve
COVID-19 symptoms in its early stages.

But he added there was no evidence to back up the French
claims that ibuprofen worsens COVID-19 symptoms, saying the
formulation being used in the trial should lessen the possible
side effects.

"There's no way these early reports would've been talking
about this different formulation," Mehta told Reuters.

"The trial is the right forum in which to test the side
effects and to test the efficacy."

(Reporting by Alistair Smout; editing by Emelia
Sithole-Matarise and Ed Osmond)

More News
19 Jan 2021 09:38

UK BROKER RATINGS SUMMARY: Exane BNP Upgrades RELX To Neutral

UK BROKER RATINGS SUMMARY: Exane BNP Upgrades RELX To Neutral

Read more
12 Jan 2021 09:53

UK BROKER RATINGS SUMMARY: Berenberg Starts Coverage On Avast At Buy

UK BROKER RATINGS SUMMARY: Berenberg Starts Coverage On Avast At Buy

Read more
4 Jan 2021 09:38

UPDATE 2-UK shares gain on vaccine hopes; Ladbrokes owner soars

(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window)* UK's FTSE 100 gains most in four weeks* Plumbing parts maker Ferguson sells UK business* Miner Rio Tinto biggest gainer in FTSE 100* FTSE 1...

Read more
21 Dec 2020 17:07

LONDON MARKET CLOSE: Stocks Sold Off As New Virus Strain Fears Bite

LONDON MARKET CLOSE: Stocks Sold Off As New Virus Strain Fears Bite

Read more
21 Dec 2020 09:59

UPDATE 2-European stocks hit by worst selloff in almost 2 months on new virus strain fears

(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window)* Oil, banks lead sectoral declines* Shell to write down value of oil and gas assets again* Frankfurt shares of BioNtech jump 1.7% (Updates ...

Read more
21 Dec 2020 09:31

UK BROKER RATINGS SUMMARY: Berenberg Downgrades Premier Oil To Sell

UK BROKER RATINGS SUMMARY: Berenberg Downgrades Premier Oil To Sell

Read more
17 Dec 2020 16:29

UK EXECUTIVE CHANGE SUMMARY: Kingspan Insulation Boards MD To Depart

UK EXECUTIVE CHANGE SUMMARY: Kingspan Insulation Boards MD To Depart

Read more
15 Dec 2020 13:40

Tuesday broker round-up

(Sharecast News) - Calisen: Credit Suisse downgrades to neutral with a target price of 261p.

Read more
15 Dec 2020 09:37

UK BROKER RATINGS SUMMARY: JPMorgan Downgrades Berkeley, Raises Redrow

UK BROKER RATINGS SUMMARY: JPMorgan Downgrades Berkeley, Raises Redrow

Read more
9 Dec 2020 00:12

INSIGHT-Good luck finding a PlayStation 5: Walmart and other retailers battle ‘bots’ snatching up hot products

(Adds quote from Walmart spokesman)By Richa Naidu and Melissa FaresCHICAGO/NEW YORK, Dec 8 (Reuters) - Seven times last month, Benjamin Karmis, a 26-year-old priest from Wheaton, Illinois, failed to get his hands on the latest Sony PlayStation 5 vi...

Read more
30 Nov 2020 09:18

Indivior Says Reckitt Bencksier Claim Is "Without Merit"

Indivior Says Reckitt Bencksier Claim Is "Without Merit"

Read more
30 Nov 2020 07:49

Indivior says £1.1bn Reckitt claim 'without merit'

(Sharecast News) - Indivior said on Monday that a £1.1bn claim against it by consumer goods group Reckitt Benckiser, which has yet to be served on the opioid addiction treatment maker, is "without merit" and that it has "strong grounds" for defending itself should the claim be served.

Read more
27 Nov 2020 17:03

LONDON MARKET CLOSE: Muted Friday Unable To Dent Positive Week

LONDON MARKET CLOSE: Muted Friday Unable To Dent Positive Week

Read more
27 Nov 2020 12:23

REPEAT: LONDON MARKET: Indivior Down 45% On GBP1 Billion Reckitt Claim

REPEAT: LONDON MARKET: Indivior Down 45% On GBP1 Billion Reckitt Claim

Read more
27 Nov 2020 12:12

LONDON MARKET MIDDAY: Indivior Drops On Reckiitt's GBP1 Billion Claim

LONDON MARKET MIDDAY: Indivior Drops On Reckiitt's GBP1 Billion Claim

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.